Hormone Therapy for Perimenopausal and Menopausal Women: A Holistic Approach
- randrson
- Jul 4, 2025
- 5 min read

At Cascade Mind and Body Clinic, we recognize that the journey through perimenopause and menopause can be deeply transformative, yet often challenging. Hormonal shifts during this time can significantly impact a woman’s mood, sleep, energy, cognition, sexual function, and long-term health. Fortunately, individualized hormone therapy (HT) and strategic supplementation can help restore balance, vitality, and well-being.
Understanding Perimenopause and Menopause
Perimenopause usually begins in a woman's 40s and may last 4 to 10 years. Hormone levels fluctuate, leading to symptoms such as insomnia, anxiety, and irregular periods. Menopause is defined as the absence of menstrual periods for 12 consecutive months, typically occurring between ages 45 and 55.
How We Test Hormones at Cascade Mind and Body Clinic
We use comprehensive testing to evaluate hormone status and guide therapy:
Serum blood testing for estradiol, FSH, LH, progesterone, free and total testosterone, DHEA, SHBG, and TSH.
DUTCH testing for advanced hormone metabolite and adrenal assessment.
Salivary testing in select cases to assess circadian rhythm or adrenal status.
What Each Hormone Tells Us
Hormone | Why It Matters | Symptoms of Imbalance | References |
Estradiol (E2) | Regulates thermoregulation, bone remodeling, cognition, cardiovascular health, urogenital tissue, and skin. | Hot flashes, night sweats, vaginal dryness, memory issues, mood swings, bone loss. | NAMS, 2022; Manson et al., 2017; Rocca et al., 2011 |
Progesterone | Balances estrogen, supports mood, reduces anxiety, promotes GABA activity for sleep, regulates the uterine lining. | Anxiety, insomnia, mood swings, irritability, irregular bleeding. | Prior, 2018; Hitchcock & Prior, 2023; Genazzani et al., 2018 |
Testosterone | Supports libido, energy, cognition, muscle mass, mood, and bone strength. | Low libido, fatigue, depression, brain fog, muscle loss. | Davis et al., 2019; Nappi et al., 2020; Islam et al., 2019 |
FSH | Increases as ovarian function declines. Marker of menopause, not a direct cause of symptoms. | Often associated with severe hot flashes, irritability, and brain fog. | Burger et al., 2007 |
DHEA | Precursor to estrogen/testosterone; supports mood, libido, immune function, and energy. | Fatigue, low libido, depression, poor stress tolerance. | Labrie et al., 2005 |
Hormone Therapy Benefits
When hormone therapy is tailored to an individual's biology and timing, it can:
Alleviate vasomotor symptoms (hot flashes, night sweats)
Improve sleep, mood, and energy
Enhance sexual function and vaginal health
Support cognitive clarity
Prevent osteoporosis and maintain bone density (NAMS, 2022)
When to Start Hormone Therapy: The Therapeutic Window
The ideal time to begin HT is within 10 years of menopause onset or before age 60. This is known as the therapeutic window, when estrogen receptors are most responsive, and vascular risk is lowest (Hodis & Sarrel, 2018).
Outside this window, particularly >10 years post-menopause, estrogen therapy may slightly increase the risk of stroke or heart attack if not managed carefully due to pre-existing vascular changes (Manson et al., 2017).
Can Women Over 70 or 15+ Years Post-Menopause Use HT?
Yes—with caution and personalization. While systemic estrogen may pose cardiovascular risks in this group, testosterone and progesterone can still be beneficial:
Micronized progesterone improves sleep and anxiety without increasing cardiovascular or breast cancer risk (Hitchcock & Prior, 2023; Prior, 2018; Fournier et al., 2005).
Testosterone improves libido, energy, mood, and cognition even in late postmenopause, with no increase in cardiovascular or breast cancer risk when dosed physiologically (Davis et al., 2019; Islam et al., 2019).
Delivery Methods
Method | Pros | Notes |
Patch | Stable blood levels, bypasses liver | Ideal for estradiol |
Gel/Cream | Flexible, bioidentical | May transfer with contact |
Oral | Convenient (esp. for progesterone) | Higher clot risk for estrogen |
Troche/Sublingual | Fast absorption, avoids digestion | Common for testosterone, DHEA |
Vaginal (local) | Targets dryness, UTIs | Minimal systemic effects |
Bioidentical vs. Synthetic Hormones
Type | Source | Pros | Common Examples |
Bioidentical | Plant-derived; identical to human hormones | Safer, better tolerated | Estradiol patch/gel, Prometrium, compounded testosterone |
Synthetic | Not structurally identical | More side effects | Medroxyprogesterone, Premarin |
At Cascade Mind and Body Clinic, we prioritize bioidentical hormones supported by safety and efficacy data.
Supplements to Support Hormonal Balance
Supplement | Use | Thorne Product |
Magnesium bisglycinate | Sleep, anxiety, cramps | Magnesium Bisglycinate |
Vitamin D3 + K2 | Bone, cardiovascular health | D/K2 Liquid |
DIM | Estrogen metabolism | DIM Advantage |
Omega-3s | Mood, cognition, inflammation | Super EPA |
Rhodiola, Ashwagandha | Stress, energy, libido | Phytisone |
Symptoms Hormone Therapy Can Relieve
Hot flashes, night sweats
Anxiety, depression, mood swings
Poor sleep or early morning awakening
Brain fog, forgetfulness
Vaginal dryness, painful intercourse
Fatigue, apathy
Muscle or bone loss
Low libido, weight gain
Urinary urgency or recurrent UTIs
Long-Term Consequences of Hormonal Depletion
Without appropriate support, long-term hormone deficiencies can increase the risk for:
Osteoporosis and fractures
Cardiovascular disease
Cognitive decline and dementia
Skin aging and muscle loss
Chronic fatigue and mood disorders
Urinary incontinence and prolapse
Final Thoughts
Hormone therapy is about more than symptom relief—it’s about restoring your foundation of health and vitality. At Cascade Mind and Body Clinic, we believe in empowering women with evidence-based options, advanced diagnostics, and individualized care. Whether you're navigating early perimenopause or have been postmenopausal for over a decade, we're here to help you feel like yourself again.
References
Burger, H. G., Hale, G. E., Robertson, D. M., & Dennerstein, L. (2007). A review of hormonal changes during the menopausal transition: Focus on findings from the Melbourne Women's Midlife Health Project. Human Reproduction Update, 13(6), 559–556. https://doi.org/10.1093/humupd/dmm020
Davis, S. R., Baber, R., & Panay, N. (2019). Global consensus position statement on the use of testosterone therapy for women. Climacteric, 22(5), 429–435. https://doi.org/10.1080/13697137.2019.1637074
de Lignières, B. (1999). Oral micronized progesterone: Pharmacokinetics and therapeutic applications. Clinical Therapeutics, 21(1), 41–60. https://doi.org/10.1016/S0149-2918(00)88279-3
Fournier, A., Berrino, F., & Clavel-Chapelon, F. (2005). Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. Breast Cancer Research and Treatment, 88(3), 219–225. https://doi.org/10.1007/s10549-004-9460-3
Genazzani, A. R., Stomati, M., & Luisi, M. (2018). Progesterone and the central nervous system: An overview. Steroids, 140, 90–99. https://doi.org/10.1016/j.steroids.2018.10.005
Hitchcock, C. L., & Prior, J. C. (2023). Oral micronized progesterone for perimenopausal night sweats and sleep problems: A randomized controlled trial. Menopause, 30(1), 42–49. https://doi.org/10.1097/GME.0000000000002105
Hodis, H. N., & Sarrel, P. M. (2018). Menopausal hormone therapy and the risk of cardiovascular disease and all-cause mortality: A review of meta-analyses. Climacteric, 21(4), 371–378. https://doi.org/10.1080/13697137.2018.1469755
Bolour, S., & Braunstein, G. (2005). Testosterone therapy in women: a review. International journal of impotence research, 17(5), 399–408. https://doi.org/10.1038/sj.ijir.3901334
Labrie, F., Bélanger, A., Cusan, L., Gomez, J. L., & Martel, C. (2005). Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. Journal of Clinical Endocrinology & Metabolism, 90(11), 6255–6261. https://doi.org/10.1210/jc.2005-1484
Manson, J. E., Chlebowski, R. T., Stefanick, M. L., et al. (2017). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA, 318(10), 927–938. https://doi.org/10.1001/jama.2017.11217
Nappi, R. E., Martini, E., & Cucinella, L. (2020). Hypoactive sexual desire disorder in menopausal women: Pathophysiology and pharmacological management. Drugs in Context, 9, 1–10. https://doi.org/10.7573/dic.2019-11-1
North American Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767–794. https://doi.org/10.1097/GME.0000000000002028
Prior, J. C. (2018). Progesterone for symptom control during the menopausal transition—Addressing the evidence. CMAJ, 190(16), E516–E521. https://doi.org/10.1503/cmaj.170984




Comments